{"id":53869,"date":"2018-12-19T17:51:57","date_gmt":"2018-12-19T16:51:57","guid":{"rendered":"https:\/\/www.aspeninstitute.it\/attivita\/precision-medicine-and-healthcare-can-it-ever-be-sustainable\/"},"modified":"2023-02-09T19:30:58","modified_gmt":"2023-02-09T18:30:58","slug":"precision-medicine-and-healthcare-can-it-ever-be-sustainable","status":"publish","type":"attivita","link":"https:\/\/www.aspeninstitute.it\/en\/attivita\/precision-medicine-and-healthcare-can-it-ever-be-sustainable\/","title":{"rendered":"Precision medicine and healthcare: can it ever be sustainable?"},"content":{"rendered":"

Major innovations originate from the convergence between disciplines, technologies, productive systems or lifestyles. The Life Sciences are experiencing one of these moments: the synergies between the progress of Science and Technology generate on the one hand more knowledge about the genetic characteristics of individuals, on the other, the ability to elaborate an enormous mass of data to improve the diagnosis, prevent diseases, find more effective therapies.<\/div>\n
We are thus living an exciting phase of innovation and the pharmaceutical companies are committed to developing 15,000 medicines worldwide, with an acceleration that is unparalleled in history. The progress of research makes it possible to respond to growing health needs and this product innovation requires great changes within the welfare processes.<\/div>\n
The most remarkable transformation is innovation that changes the lives of patients.<\/div>\n
Just to make a few examples today 2 people out of 3 who are diagnosed with cancer survive after 5 years, 30 years ago the ratio did not reach 1 out of 3; HIV has become a chronic disease and a twenty-year-old who is diagnosed with HIV has a life expectancy of 70 years; hepatitis C is curable; mortality from cardiovascular disease has reduced by 30% in 10 years.<\/div>\n
<\/div>\n
Innovation debates are often focused on its cost. But this is very limiting. We must all be proud of innovation, with the primary objective of ensuring the widest access as quickly as possible.Thanks to the analysis of the human genome it is possible to define more targeted and effective therapies that also reduce side effects. Personalized therapies account for more than 20% of the authorized drugs and 42% of those under development, even 73% in oncology. In this sense, precision medicine will be able to generate an even more disruptive innovation, improving the care for a society that is in turn changing (for ageing, chronicity, demographic trends) and therefore requires new approaches and methodologies.<\/div>\n
There must be a transition from Precision Medicine to Precision Health, that is an innovative paradigm based on the continuity between diagnosis and treatment and between prediction and prevention. With these trends, medicines are no longer “just” products but part of a care process, combined for example with devices, diagnostics, med tech, homecare.<\/div>\n
In Life Science new products and new processes require new regulatory models.<\/div>\n
Significant innovative processes are affecting many sectors, but there is a peculiarity as for Life Sciences: the importance and pervasiveness of regulation, which is fundamental to generate innovation and make it accessible and easily manageable for Patients.<\/div>\n
<\/div>\n
In a precision health paradigm, the organization of healthcare systems in all its aspects must become precision-based as well. And this is as important as the innovation stemming from R&D pipeline. The overall system architecture in fact must evolve accordingly and in particular regulation must adopt a holistic and outcome-based view, which does not measure the cost of any single service but the total value of the diagnostic, therapeutic and care path, also taking into account the costs avoided by appropriate therapies in the other items of healthcare or social expenditure.<\/div>\n
It is a necessary evolution from many points of view: it is Patient-centered; it can really lead to sustainability, which is referred to total spending and not to its individual components; it makes a greater flexibility possible to invest resources where they are needed according to the technological and social innovation.<\/div>\n
Today, thanks to technology, it is possible to measure the costs and the results of therapies on a large scale, which is a fundamental objective to reorganize the NHS. It is worth taking into account the savings obtained thanks to vaccinations; or the possibilities of treating chronic diseases avoiding complications or their degeneration, and delaying the need for assistance; or considering the benefit of drugs that avoid hospitalizations, generating savings and helping patients to better manage their pathologies; or, finally, thinking about the genetic tests that can be used to verify the efficacy of treatments on each single Patient.<\/div>\n
<\/div>\n
Precision medicine and digital transformation in Life Sciences entail strong product innovations and require great innovation of processes, driven by the capability to integrate science, technology, skills and social context with one another. In order to combine personalization of care and universalism, the focus must shift from cost control to person\u2019s care, access to treatment and efficiency of the entire care process. Healthcare expenditures are indeed an investment, from a social point of view, because of the possibility of avoiding costs and for the effects on growth – in terms of investments, employment and productivity – and therefore on the capacity to generate resources, without which the match for the welfare sustainability is lost from the very start.<\/div>\n
<\/div>\n
A goal that requires vision, new skills, multidisciplinarity and comparison between Research, Industry and Regulators to find innovative solutions also suitable for the new context: because the challenges of a quickly changing world must be faced with new approaches.Being aware that the mechanisms of healthcare systems are extremely complex and affect people’s lives, just when they are most in need, then innovations must be communicated in a simple and readily understandable way, so as to share with all the stakeholders the need for change and the big opportunities this may offer.<\/div><\/p>\n","protected":false},"excerpt":{"rendered":"

Major innovations originate from the convergence between disciplines, technologies, productive systems or lifestyles.<\/p>\n","protected":false},"author":2355,"featured_media":0,"template":"","meta":{"_acf_changed":false,"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","neve_meta_reading_time":"","_themeisle_gutenberg_block_has_review":false,"footnotes":""},"freetags":[],"tipologiaattivita":[1391],"tag_tecnica":[],"temi_aspen":[],"attivita_internaz_in_essere":[],"attivita_internaz_concluse":[],"studi_e_ricerche":[],"primi_nel_tema":[],"tag_tecnici":[],"tag_formato":[2885],"class_list":["post-53869","attivita","type-attivita","status-publish","hentry","tipologiaattivita-aspen-seminars-for-leaders-en","tag_formato-seminar"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.aspeninstitute.it\/en\/wp-json\/wp\/v2\/attivita\/53869","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.aspeninstitute.it\/en\/wp-json\/wp\/v2\/attivita"}],"about":[{"href":"https:\/\/www.aspeninstitute.it\/en\/wp-json\/wp\/v2\/types\/attivita"}],"author":[{"embeddable":true,"href":"https:\/\/www.aspeninstitute.it\/en\/wp-json\/wp\/v2\/users\/2355"}],"version-history":[{"count":1,"href":"https:\/\/www.aspeninstitute.it\/en\/wp-json\/wp\/v2\/attivita\/53869\/revisions"}],"predecessor-version":[{"id":114028,"href":"https:\/\/www.aspeninstitute.it\/en\/wp-json\/wp\/v2\/attivita\/53869\/revisions\/114028"}],"wp:attachment":[{"href":"https:\/\/www.aspeninstitute.it\/en\/wp-json\/wp\/v2\/media?parent=53869"}],"wp:term":[{"taxonomy":"freetags","embeddable":true,"href":"https:\/\/www.aspeninstitute.it\/en\/wp-json\/wp\/v2\/freetags?post=53869"},{"taxonomy":"tipologiaattivita","embeddable":true,"href":"https:\/\/www.aspeninstitute.it\/en\/wp-json\/wp\/v2\/tipologiaattivita?post=53869"},{"taxonomy":"tag_tecnica","embeddable":true,"href":"https:\/\/www.aspeninstitute.it\/en\/wp-json\/wp\/v2\/tag_tecnica?post=53869"},{"taxonomy":"temi_aspen","embeddable":true,"href":"https:\/\/www.aspeninstitute.it\/en\/wp-json\/wp\/v2\/temi_aspen?post=53869"},{"taxonomy":"attivita_internaz_in_essere","embeddable":true,"href":"https:\/\/www.aspeninstitute.it\/en\/wp-json\/wp\/v2\/attivita_internaz_in_essere?post=53869"},{"taxonomy":"attivita_internaz_concluse","embeddable":true,"href":"https:\/\/www.aspeninstitute.it\/en\/wp-json\/wp\/v2\/attivita_internaz_concluse?post=53869"},{"taxonomy":"studi_e_ricerche","embeddable":true,"href":"https:\/\/www.aspeninstitute.it\/en\/wp-json\/wp\/v2\/studi_e_ricerche?post=53869"},{"taxonomy":"primi_nel_tema","embeddable":true,"href":"https:\/\/www.aspeninstitute.it\/en\/wp-json\/wp\/v2\/primi_nel_tema?post=53869"},{"taxonomy":"tag_tecnici","embeddable":true,"href":"https:\/\/www.aspeninstitute.it\/en\/wp-json\/wp\/v2\/tag_tecnici?post=53869"},{"taxonomy":"tag_formato","embeddable":true,"href":"https:\/\/www.aspeninstitute.it\/en\/wp-json\/wp\/v2\/tag_formato?post=53869"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}